Guidelines for time-to-event endpoint definitions in randomized cancer trials for sarcomas and GIST: Results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

被引：0
|
作者：
Bellera, C. [1 ]
Ouali, M. [2 ]
Penel, N. [3 ]
Litiere, S. [4 ]
Casali, P. [5 ]
Bonvalot, S. [6 ]
Nielsen, O. S. [7 ]
Delannes, M. [2 ]
Mathoulin-Pelissier, S. [1 ]
机构：
[1] Inst Bergonie, Comprehensice Canc Ctr, Bordeaux, France
[2] Inst Claudius Regaud, Comprehensice Canc Ctr, Toulouse, France
[3] Ctr Oscar Lambret, F-59020 Lille, France
[4] European Org Res Treatment Canc, Brussels, Belgium
[5] Ist Nazl Tumori, Brussels, Belgium
[6] Inst Gustave Roussy, Comprehensice Canc Ctr, Villejuif, France
[7] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3817
引用
收藏
页码：S881 / S881
页数：1
相关论文
共 50 条
  • [1] Guidelines for time-to-event endpoints' definitions in cancer randomized controlled trials (RCTs) for breast cancer - results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
    Gourgou-Bourgade, S.
    Dabakuyo-Yonli, S.
    Cameron, D.
    Cardoso, F.
    Poortmans, P.
    Asselain, B.
    Azria, D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S441 - S442
  • [2] Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
    Bellera, C. A.
    Penel, N.
    Ouali, M.
    Bonvalot, S.
    Casali, P. G.
    Nielsen, O. S.
    Delannes, M.
    Litiere, S.
    Bonnetain, F.
    Dabakuyo, T. S.
    Benjamin, R. S.
    Blay, J. -Y.
    Bui, B. N.
    Collin, F.
    Delaney, T. F.
    Duffaud, F.
    Filleron, T.
    Fiore, M.
    Gelderblom, H.
    George, S.
    Grimer, R.
    Grosclaude, P.
    Gronchi, A.
    Haas, R.
    Hohenberger, P.
    Issels, R.
    Italiano, A.
    Jooste, V.
    Krarup-Hansen, A.
    Le Pechoux, C.
    Mussi, C.
    Oberlin, O.
    Patel, S.
    Piperno-Neumann, S.
    Raut, C.
    Ray-Coquard, I.
    Rutkowski, P.
    Schuetze, S.
    Sleijfer, S.
    Stoeckle, E.
    Van Glabbeke, M.
    Woll, P.
    Gourgou-Bourgade, S.
    Mathoulin-Pelissier, S.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (05) : 865 - 872
  • [3] Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
    Gourgou-Bourgade, S.
    Cameron, D.
    Poortmans, P.
    Asselain, B.
    Azria, D.
    Cardoso, F.
    A'Hern, R.
    Bliss, J.
    Bogaerts, J.
    Bonnefoi, H.
    Brain, E.
    Cardoso, M. J.
    Chibaudel, B.
    Coleman, R.
    Cufer, T.
    Dal Lago, L.
    Dalenc, F.
    De Azambuja, E.
    Debled, M.
    Delaloge, S.
    Filleron, T.
    Gligorov, J.
    Gutowski, M.
    Jacot, W.
    Kirkove, C.
    MacGrogan, G.
    Michiels, S.
    Negreiros, I.
    Offersen, B. V.
    Llorca, F. Penault
    Pruneri, G.
    Roche, H.
    Russell, N. S.
    Schmitt, F.
    Servent, V.
    Thuerlimann, B.
    Untch, M.
    van der Hage, J. A.
    van Tienhoven, G.
    Wildiers, H.
    Yarnold, J.
    Bonnetain, F.
    Mathoulin-Pelissier, S.
    Bellera, C.
    Dabakuyo-Yonli, T. S.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (05) : 873 - 879
  • [4] Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) (vol 26, pg 873, 2015)
    Gourgou-Bourgade, S.
    Cameron, D.
    Poortmans, P.
    Asselain, B.
    Azria, D.
    Cardoso, F.
    A'Hern, R.
    Bliss, J.
    Bogaerts, J.
    Bonnefoi, H.
    Brain, E.
    Cardoso, M. J.
    Chibaudel, B.
    Coleman, R.
    Cufer, T.
    Dal Lago, L.
    Dalenc, F.
    De Azambuja, E.
    Debled, M.
    Delaloge, S.
    Filleron, T.
    Gligorov, J.
    Gutowski, M.
    Jacot, W.
    Kirkove, C.
    MacGrogan, G.
    Michiels, S.
    Negreiros, I.
    Offersen, B. V.
    Llorca, F. Penault
    Pruneri, G.
    Roche, H.
    Russell, N. S.
    Schmitt, F.
    Servent, V.
    Thuerlimann, B.
    Untch, M.
    Van der Hage, J. A.
    van Tienhoven, G.
    Wildiers, H.
    Yarnold, J.
    Bonnetain, F.
    Mathoulin-Pelissier, S.
    Bellera, C.
    Dabakuyo-Yonli, T. S.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (12) : 2505 - 2506
  • [5] Guidelines for the definitions of time-to-event endpoints in randomized clinical trials: Results of the DATECAN Project for Sarcomas and GISTs
    Bellera, Carine A.
    Ouali, Monia
    Penel, Nicolas
    Bonvalot, Sylvie
    Casali, Paolo Giovanni
    Delannes, Martine
    Nielsen, Ole Steen
    Mathoulin-Pelissier, Simone
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials
    Bellera, Carine A.
    Pulido, Marina
    Gourgou, Sophie
    Collette, Laurence
    Doussau, Adelaide
    Kramar, Andrew
    Dabakuyo, Tienhan Sandrine
    Ouali, Monia
    Auperin, Anne
    Filleron, Thomas
    Fortpied, Catherine
    Le Tourneau, Christophe
    Paoletti, Xavier
    Mauer, Murielle
    Mathoulin-Pelissier, Simone
    Bonnetain, Franck
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (04) : 769 - 781
  • [7] Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)
    Bonnetain, Franck
    Bonsing, Bert
    Conroy, Thierry
    Dousseau, Adelaide
    Glimelius, Bengt
    Haustermans, Karin
    Lacaine, Francois
    Van Laethem, Jean Luc
    Aparicio, Thomas
    Aust, Daniela
    Bassi, Claudio
    Berger, Virginie
    Chamorey, Emmanuel
    Chibaudel, Benoist
    Dahan, Laeticia
    De Gramont, Aimery
    Delpero, Jean Robert
    Dervenis, Christos
    Ducreux, Michel
    Gal, Jocelyn
    Gerber, Erich
    Ghaneh, Paula
    Hammel, Pascal
    Hendlisz, Alain
    Jooste, Valerie
    Labianca, Roberto
    Latouche, Aurelien
    Lutz, Manfred
    Macarulla, Teresa
    Malka, David
    Mauer, Muriel
    Mitry, Emmanuel
    Neoptolemos, John
    Pessaux, Patrick
    Sauvanet, Alain
    Tabernero, Josep
    Taieb, Julien
    van Tienhoven, Geertjan
    Gourgou-Bourgade, Sophie
    Bellera, Carine
    Mathoulin-Pelissier, Simone
    Collette, Laurence
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (17) : 2983 - 2993
  • [8] Guidelines for the definitions of time-to-event endpoints in randomized clinical trials: Results of the datecan project for breast group
    Gourgou-Bourgade, S.
    Dabakuyo-Yonli, S.
    Cameron, D.
    Cardoso, F.
    Poortmans, P.
    Asselain, B.
    Azria, D.
    [J]. CANCER RESEARCH, 2013, 73
  • [9] Guidelines for the definitions of time-to-event endpoints in randomized clinical trials: Results of the DATECAN Project for Breast Group
    Gourgou, Sophie
    Dabakuyo, Tienhan Sandrine
    Asselain, Bernard
    Azria, David
    Cameron, David A.
    Cardoso, Fatima
    Poortmans, Philip M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN projectaEuro
    Kramar, A.
    Negrier, S.
    Sylvester, R.
    Joniau, S.
    Mulders, P.
    Powles, T.
    Bex, A.
    Bonnetain, F.
    Bossi, A.
    Bracarda, S.
    Bukowski, R.
    Catto, J.
    Choueiri, T. K.
    Crabb, S.
    Eisen, T.
    El Demery, M.
    Fitzpatrick, J.
    Flamand, V.
    Goebell, P. J.
    Gravis, G.
    Houede, N.
    Jacqmin, D.
    Kaplan, R.
    Malavaud, B.
    Massard, C.
    Melichar, B.
    Mourey, L.
    Nathan, P.
    Pasquier, D.
    Porta, C.
    Pouessel, D.
    Quinn, D.
    Ravaud, A.
    Rolland, F.
    Schmidinger, M.
    Tombal, B.
    Tosi, D.
    Vauleon, E.
    Volpe, A.
    Wolter, P.
    Escudier, B.
    Filleron, T.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (12) : 2392 - 2398
12345